Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,071 INR | -0.76% | +3.05% | +25.43% |
06:09am | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
04-25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
Business Summary
Number of employees: 15,556
Sales per Business
INR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 123,049 | 100.0 % | 129,901 | 100.0 % | +5.57% |
Sales per region
INR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
India
34.4
%
| 43,809 | 35.6 % | 44,675 | 34.4 % | +1.98% |
North America
25.0
%
| 32,035 | 26.0 % | 32,484 | 25.0 % | +1.40% |
Europe
17.7
%
| 20,047 | 16.3 % | 23,047 | 17.7 % | +14.97% |
Rest of the World
17.3
%
| 21,031 | 17.1 % | 22,414 | 17.3 % | +6.58% |
Latin America
5.6
%
| 6,127 | 5.0 % | 7,281 | 5.6 % | +18.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 11/10/98 | |
Ulhas Dhuppad
PSD | President | - | - |
Alind Sharma
PSD | President | - | 31/05/22 |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 15/11/17 |
Nikhil Amin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Harish Kuber
CMP | Compliance Officer | - | 01/02/17 |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 31/12/82 |
Cherylann Pinto
BRD | Director/Board Member | 56 | 05/10/99 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 13/08/20 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 05/10/99 |
Chief Executive Officer | 54 | 11/10/98 | |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 31/12/82 |
Director/Board Member | 83 | 13/08/09 | |
Director/Board Member | 68 | 09/02/23 | |
Director/Board Member | 48 | 31/03/19 | |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 15/11/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 282,188,156 | 138,368,096 ( 49.03 %) | 0 | 49.03 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
9,609,571 | 7.84% | 89,329,419 $ |
Company contact information
Glenmark Pharmaceuticals Ltd.
Glenmark House Off Western Express Highway
400099, Mumbai
+91 22 4018 9999
http://www.glenmarkpharma.comGroup companies
Name | Category and Sector |
---|---|
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Sector
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.43% | 3.65B | |
+20.81% | 43.34B | |
+20.44% | 21.96B | |
+13.30% | 14.09B | |
+12.97% | 13.64B | |
+39.74% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- GLENMARK Stock
- Company Glenmark Pharmaceuticals Limited